Epigenetic biomarkers for clinical outcomes and mechanisms driving emergence of drug resistance in ovarian cancer
Epithelial ovarian cancer (EOC) has a poor prognosis, with a 5 year survival rate of ~40%. A major therapeutic barrier is disease chemoresistant to the standard therapeutic regimen of taxol and platinum. Efficacious therapies in chemoresistant disease, a fuller understanding of the molecular mechani...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
Imperial College London
2017
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.733208 |